What question did this study set out to answer?

To evaluate the bioequivalence of ruxolitinib extended-release compared to immediate-release formulations.

December 8, 2025BloodOpen Access

Bioequivalence of ruxolitinib once-daily extended-release vs twice-daily immediate-release tablets in healthy adults

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial assessed bioequivalence of ruxolitinib extended-release and immediate-release, indicating similar pharmacokinetic profiles.

To evaluate the bioequivalence of ruxolitinib extended-release compared to immediate-release formulations.
Open-label, randomized, 2-period, 2-way crossover design
Participants received either IR 25 mg bid or XR 55 mg qd
Blood samples collected for pharmacokinetic analysis
Steady state achieved by Day 2 for both formulations
Extended absorption time and longer half-life for XR
Bioequivalence established for key pharmacokinetic parameters with GMRs within acceptable range

Mondick et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial assessed bioequivalence of ruxolitinib extended-release and immediate-release, indicating similar pharmacokinetic profiles.